Oral PCSK9 Inhibitor Safe and Effective in Lowering Cholesterol in First Human Trial
A second study found LDL-cholesterol decreased 65% when oral MK-0616 was added to their current statin therapy for 14 days
Source: dicardiology.com
Stay updated with breaking news from Yaleb Mitchel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A second study found LDL-cholesterol decreased 65% when oral MK-0616 was added to their current statin therapy for 14 days